Pfizer S.A. de C.V.

1 similar search for Pfizer S.A. de C.V.

Pfizer, S.A. De C.V.

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

109 documents for Pfizer S.A. de C.V.

- Oscient Pharmaceuticals and Pfizer, S.A. de C.V. Announce Approval of FACTIVE Tablets in Mexico; FACTIVE-5 Now Approved for Use in Respiratory Tract Infections.
... CAP, AECB and ABS with three national field sales forces and one specialty field sales force in the ...
- Business Wire
- August 01, 2006
- Oscient Pharmaceuticals and Pfizer, S.A. de C.V. Announce Launch of FACTIVE(R) Tablets in Mexico.
... these indications with three national field sales forces and one specialty field sales force," state...
- Business Wire
- October 05, 2006
- Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
... G AstraZeneca plc; Pfizer Inc.;. ... Series; Banco Santander,. S.A....20120136......... G CVR Energy, Inc.; Samuel. ...
- Federal Register Nbr. 76 FR 77534, December 13, 2011
- Notices
- Federal Trade Commission

- Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE Tablets in Mexico; Pfizer, S.A. De C.V. to Advance Commercialization of the Fluoroquinolone Antibiotic in Mexico.
... for attaining certain regulatory and sales goals as well as royalties on future sales. Specif...
- Business Wire
- February 07, 2006
- The United States' adoption of the well-known foreign mark exception.
... recognition of products (and hopefully sales), (11) companies are eager to protect their marks ...(105) For example, in Grupo Gigante S.A. de CV v. Dallo & Co., the senior user of the mark "Gigan...See Pfizer Inc. v. Sachs, No. 08 Civ. 8065(WHP), 2008 WL 4525...
- Fordham Urban Law Journal
- Vol. 36 Nbr. 5, November 2009
- Zacks Analyst Blog Highlights: Auxilium Pharmaceuticals, Inc., Pfizer, Cognizant Technology Solutions Corp., Neurocrine Biosciences, Inc. and Coca-Cola FEMSA S.A. de C.V.
...sales of Testim, up 20% year-over-year, $1.3 million in ...
- Business Wire
- May 08, 2009
- Zacks Analyst Blog Highlights: Cemex S.A. de C.V., Baxter International Inc., Web.com, Gilead Sciences, Inc. and Pfizer Inc.
...are problematic. . Baxter Outlook: Safe and Bullish . Baxter International (NYSE: BAX) is ...
- Business Wire
- October 21, 2008
- Research and Markets: Cough, Cold and Allergy (hay Fever) Remedies in Mexico - Forecasts to 2013 - A Giant Is Making the OTC Industry Tremble.
...It provides the latest retail sales data (2003-2008), allowing you to identify the sec...* Bayer De Mexico SA De Cv . * Boehringer Ingelheim Promeco SA De Cv . * Farm...* Novartis Farmaceutica SA De Cv . * Pfizer SA De Cv . * Procter & Gamble De Mexico SA De Cv ....
- Business Wire
- October 15, 2009
- New Report Forecasts the Outlook for Medicated Skin Care in Mexico to 2011.
...It provides the latest retail sales data (2001-2006), allowing you to identify the sec.... Companies Mentioned: Wyeth SA de CV Procter & Gamble de Mexico SA de CV Pfizer SA de C...
- Business Wire
- May 02, 2008
- Oscient Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2005; Conference Call with Senior Management Scheduled for 8:30 AM ET Today.
... sublicense of commercialization rights to Pfizer, S.A. de C.V. in Mexico." . For the fourth quarter... 2005 reflects costs related to the expanded sales force, which were largely offset by decreases in l...
- Business Wire
- March 06, 2006